NCT06795698View on ClinicalTrials.gov

The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients.

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Fractures, BoneCKD Stage 4CKD Stage 3CKD Stage 5Enoxaparin Adverse ReactionAnticoagulant-induced BleedingThromboses, Venous
Interventions
DRUG

Enoxaparin

enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2

Trial Locations (1)

44240

Hospital Civil de Guadalajara, Guadalajara

All Listed Sponsors
lead

Hospital Civil de Guadalajara

OTHER

NCT06795698 - The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients. | Biotech Hunter | Biotech Hunter